お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:去勢抵抗性前立腺がんの世界市場:治療(内分泌療法、免疫療法、化学療法、放射線療法)、地域別 - 業界分析と予測(2020年~2026年)
市場調査レポート
商品コード
988468

去勢抵抗性前立腺がんの世界市場:治療(内分泌療法、免疫療法、化学療法、放射線療法)、地域別 - 業界分析と予測(2020年~2026年)

Global Castrate-resistant Prostate Cancer Market By Therapy (Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy), By Region, Industry Analysis and Forecast, 2020 - 2026

出版日: | 発行: KBV Research | ページ情報: 英文 124 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=112.06円
去勢抵抗性前立腺がんの世界市場:治療(内分泌療法、免疫療法、化学療法、放射線療法)、地域別 - 業界分析と予測(2020年~2026年)
出版日: 2021年01月29日
発行: KBV Research
ページ情報: 英文 124 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の去勢抵抗性前立腺がん(CRPC)の市場規模は、予測期間中に8.3%のCAGRで成長する見通しで、2026年には145億米ドルに達すると予測されています。アンドロゲン遮断療法(ADC)の管理後に一般的に再発する前立腺がんの一種である去勢抵抗性前立腺がん(CRPC)は、前立腺がん市場で顕著になりつつあります。

去勢抵抗性前立腺がんの有病率の増加、新薬の採用増加、不健康なライフスタイルなどにより、市場成長が後押しされると予測されています。迅速な治療の選択肢と大手企業による研究開発への資金提供の要件なども、同市場の成長に貢献しています。

当レポートは、世界の去勢抵抗性前立腺がん市場について調査しており、市場の動向、影響を与える要因、治療・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 市場の範囲と調査手法

第2章 市場概要

  • イントロダクション
  • 市場に影響を与える主な要因

第3章 世界市場の最近の動向

第4章 市場分析:治療別

  • ホルモン療法
  • 免疫療法
  • 化学療法
  • 放射線治療

第5章 市場分析:地域別

  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ・中東・アフリカ

第6章 企業プロファイル

  • Sanofi S.A.
  • Johnson and Johnson
  • Pfizer, Inc.
  • Bayer AG
  • Abbott Laboratories
  • GlaxoSmithKline PLC (GSK)
  • Northwest Biotherapeutics, Inc.
  • Active Biotech AB
  • Astellas Pharma, Inc.
  • Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
図表

LIST OF TABLES

  • TABLE 1 Global Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 2 Global Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 3 Global Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 4 Global Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 5 Global Hormonal Therapy Market by Region, 2016 - 2019, USD Million
  • TABLE 6 Global Hormonal Therapy Market by Region, 2020 - 2026, USD Million
  • TABLE 7 Global Immunotherapy Market by Region, 2016 - 2019, USD Million
  • TABLE 8 Global Immunotherapy Market by Region, 2020 - 2026, USD Million
  • TABLE 9 Global Chemotherapy Market by Region, 2016 - 2019, USD Million
  • TABLE 10 Global Chemotherapy Market by Region, 2020 - 2026, USD Million
  • TABLE 11 Global Radiotherapy Market by Region, 2016 - 2019, USD Million
  • TABLE 12 Global Radiotherapy Market by Region, 2020 - 2026, USD Million
  • TABLE 13 Global Castrate-resistant Prostate Cancer Market by Region, 2016 - 2019, USD Million
  • TABLE 14 Global Castrate-resistant Prostate Cancer Market by Region, 2020 - 2026, USD Million
  • TABLE 15 North America Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 16 North America Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 17 North America Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 18 North America Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 19 North America Hormonal Therapy Market by Country, 2016 - 2019, USD Million
  • TABLE 20 North America Hormonal Therapy Market by Country, 2020 - 2026, USD Million
  • TABLE 21 North America Immunotherapy Market by Country, 2016 - 2019, USD Million
  • TABLE 22 North America Immunotherapy Market by Country, 2020 - 2026, USD Million
  • TABLE 23 North America Chemotherapy Market by Country, 2016 - 2019, USD Million
  • TABLE 24 North America Chemotherapy Market by Country, 2020 - 2026, USD Million
  • TABLE 25 North America Radiotherapy Market by Country, 2016 - 2019, USD Million
  • TABLE 26 North America Radiotherapy Market by Country, 2020 - 2026, USD Million
  • TABLE 27 North America Castrate-resistant Prostate Cancer Market by Country, 2016 - 2019, USD Million
  • TABLE 28 North America Castrate-resistant Prostate Cancer Market by Country, 2020 - 2026, USD Million
  • TABLE 29 US Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 30 US Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 31 US Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 32 US Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 33 Canada Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 34 Canada Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 35 Canada Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 36 Canada Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 37 Mexico Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 38 Mexico Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 39 Mexico Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 40 Mexico Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 41 Rest of North America Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 42 Rest of North America Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 43 Rest of North America Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 44 Rest of North America Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 45 Europe Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 46 Europe Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 47 Europe Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 48 Europe Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 49 Europe Hormonal Therapy Market by Country, 2016 - 2019, USD Million
  • TABLE 50 Europe Hormonal Therapy Market by Country, 2020 - 2026, USD Million
  • TABLE 51 Europe Immunotherapy Market by Country, 2016 - 2019, USD Million
  • TABLE 52 Europe Immunotherapy Market by Country, 2020 - 2026, USD Million
  • TABLE 53 Europe Chemotherapy Market by Country, 2016 - 2019, USD Million
  • TABLE 54 Europe Chemotherapy Market by Country, 2020 - 2026, USD Million
  • TABLE 55 Europe Radiotherapy Market by Country, 2016 - 2019, USD Million
  • TABLE 56 Europe Radiotherapy Market by Country, 2020 - 2026, USD Million
  • TABLE 57 Europe Castrate-resistant Prostate Cancer Market by Country, 2016 - 2019, USD Million
  • TABLE 58 Europe Castrate-resistant Prostate Cancer Market by Country, 2020 - 2026, USD Million
  • TABLE 59 Germany Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 60 Germany Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 61 Germany Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 62 Germany Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 63 UK Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 64 UK Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 65 UK Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 66 UK Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 67 France Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 68 France Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 69 France Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 70 France Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 71 Russia Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 72 Russia Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 73 Russia Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 74 Russia Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 75 Spain Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 76 Spain Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 77 Spain Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 78 Spain Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 79 Italy Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 80 Italy Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 81 Italy Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 82 Italy Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 83 Rest of Europe Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 84 Rest of Europe Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 85 Rest of Europe Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 86 Rest of Europe Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 87 Asia Pacific Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 88 Asia Pacific Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 89 Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 90 Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 91 Asia Pacific Hormonal Therapy Market by Country, 2016 - 2019, USD Million
  • TABLE 92 Asia Pacific Hormonal Therapy Market by Country, 2020 - 2026, USD Million
  • TABLE 93 Asia Pacific Immunotherapy Market by Country, 2016 - 2019, USD Million
  • TABLE 94 Asia Pacific Immunotherapy Market by Country, 2020 - 2026, USD Million
  • TABLE 95 Asia Pacific Chemotherapy Market by Country, 2016 - 2019, USD Million
  • TABLE 96 Asia Pacific Chemotherapy Market by Country, 2020 - 2026, USD Million
  • TABLE 97 Asia Pacific Radiotherapy Market by Country, 2016 - 2019, USD Million
  • TABLE 98 Asia Pacific Radiotherapy Market by Country, 2020 - 2026, USD Million
  • TABLE 99 Asia Pacific Castrate-resistant Prostate Cancer Market by Country, 2016 - 2019, USD Million
  • TABLE 100 Asia Pacific Castrate-resistant Prostate Cancer Market by Country, 2020 - 2026, USD Million
  • TABLE 101 China Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 102 China Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 103 China Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 104 China Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 105 Japan Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 106 Japan Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 107 Japan Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 108 Japan Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 109 India Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 110 India Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 111 India Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 112 India Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 113 South Korea Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 114 South Korea Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 115 South Korea Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 116 South Korea Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 117 Singapore Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 118 Singapore Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 119 Singapore Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 120 Singapore Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 121 Malaysia Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 122 Malaysia Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 123 Malaysia Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 124 Malaysia Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 125 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 126 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 127 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 128 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 129 LAMEA Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 130 LAMEA Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 131 LAMEA Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 132 LAMEA Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 133 LAMEA Hormonal Therapy Market by Country, 2016 - 2019, USD Million
  • TABLE 134 LAMEA Hormonal Therapy Market by Country, 2020 - 2026, USD Million
  • TABLE 135 LAMEA Immunotherapy Market by Country, 2016 - 2019, USD Million
  • TABLE 136 LAMEA Immunotherapy Market by Country, 2020 - 2026, USD Million
  • TABLE 137 LAMEA Chemotherapy Market by Country, 2016 - 2019, USD Million
  • TABLE 138 LAMEA Chemotherapy Market by Country, 2020 - 2026, USD Million
  • TABLE 139 LAMEA Radiotherapy Market by Country, 2016 - 2019, USD Million
  • TABLE 140 LAMEA Radiotherapy Market by Country, 2020 - 2026, USD Million
  • TABLE 141 LAMEA Castrate-resistant Prostate Cancer Market by Country, 2016 - 2019, USD Million
  • TABLE 142 LAMEA Castrate-resistant Prostate Cancer Market by Country, 2020 - 2026, USD Million
  • TABLE 143 Brazil Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 144 Brazil Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 145 Brazil Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 146 Brazil Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 147 Argentina Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 148 Argentina Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 149 Argentina Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 150 Argentina Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 151 UAE Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 152 UAE Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 153 UAE Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 154 UAE Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 155 Saudi Arabia Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 156 Saudi Arabia Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 157 Saudi Arabia Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 158 Saudi Arabia Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 159 South Africa Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 160 South Africa Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 161 South Africa Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 162 South Africa Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 163 Nigeria Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 164 Nigeria Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 165 Nigeria Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 166 Nigeria Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 167 Rest of LAMEA Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
  • TABLE 168 Rest of LAMEA Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
  • TABLE 169 Rest of LAMEA Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
  • TABLE 170 Rest of LAMEA Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
  • TABLE 171 Key Information - Sanofi S.A.
  • TABLE 172 Key information -Johnson and Johnson
  • TABLE 173 Key Information - Pfizer, Inc.
  • TABLE 174 Key Information - Bayer AG
  • TABLE 175 Key Information - Abbott Laboratories
  • TABLE 176 Key Information - GlaxoSmithKline PLC (GSK)
  • TABLE 177 Key Information - Northwest Biotherapeutics, Inc.
  • TABLE 178 Key Information - Active Biotech AB
  • TABLE 179 key information - Astellas Pharma, Inc.
  • TABLE 180 Key Information - Dendreon Pharmaceuticals LLC

List of Figures

  • FIG 1 Methodology for the research
目次

The Global Castrate-resistant Prostate Cancer Market size is expected to reach $14.5 billion by 2026, rising at a market growth of 8.3% CAGR during the forecast period. Castrate-resistant Prostate Cancer (CRPC), a variety of prostate cancer that generally recurs after managing androgen deprivation therapy (ADC), is getting prominent in the prostate cancer market.

The global market of CRPC is estimated to rise at a notable rate, due to high unmet clinical requirements, increasing prevalence rates, limited survival benefits, and fast-emerging treatment modifications. The market growth will depend on the unique breakthrough treatments responsible for securing survival benefits. The survival benefit is helpful in controlling the peak sales and market penetration of novel approved drugs.

Shifting treatment patterns, arising untapped non-metastatic CRPC space, promising drug pipeline, and increased patient awareness are the factors that are estimated to propel the market growth. Moreover, the untapped CRPC market in the Asia-Pacific and LAMEA region will also boost the overall market growth over the forecast period. Untapped non-metastatic CRPC settings will further accelerate the market growth. However, factors like uncertain reimbursement policies, premium pricing of CRPC drugs, and lack of distinction in the mechanism of action between the approved and novel agents are expected to restrain the market growth.

The increasing prevalence of Castrate-resistant prostate cancer, rising adoption of novel drugs, coupled with an unhealthy lifestyle are the main factors predicted to boost the market growth. The requirement for fast treatment alternatives and funding in R&D by leading companies will also contribute to the growth of the market.

By Therapy

Based on Therapy, the market is segmented into Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy. The hormonal therapy category garnered the highest revenue share in the Castrate-resistant prostate cancer market in 2019. This growth is due to the presence of a huge number of approved drugs, the introduction of new drugs, and the growth of the product portfolio. Additionally, the growing advancement of innovative medicines to fulfill unmet requirements and current treatment options is estimated to propel the growth of the market for Castrate-resistant prostate cancer.

By Region

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America recorded the highest revenue share in the Castrate-resistant prostate cancer market in 2019 and is estimated to sustain the figures during the forecast period. This growth is due to the high prevalence of the disease, the existence of regional players, and supportive reimbursement policies. Changing lifestyle is another factor that adds to the prevalence of diseases.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC (GSK), Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc. and Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.).

Strategies deployed in Castrate-resistant Prostate Cancer Market

Dec-2019: Pfizer Inc. and Astellas Pharma Inc. announced that FDA approved their supplemental New Drug Application (sNDA) for XTANDI (enzalutamide). This has been used for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Oct-2019: The Janssen Pharmaceutical Companies of Johnson & Johnson announced that it received the approval from FDA for its Breakthrough Therapy Designation for niraparib, an orally-administered poly ADP-ribose polymerase (PARP) inhibitor. This inhibitor is used for the treatment of patients with BRCA1/2 gene-mutated metastatic castration-resistant prostate cancer (mCRPC).

Jul-2019: Bayer AG got FDA approval for Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi) product. This product is used for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

Mar-2019: Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi) product of Bayer AG got approval from European Commission. This product is used for the treatment of men with non-metastatic castration-resistant prostate cancer.

Jun-2018: Astellas Pharma launched 40 mg XTANDI (generic name enzalutamide) Tablets and 80 mg XTANDI Tablets in Japan for the treatment of castration-resistant prostate cancer.

Feb-2018: The Janssen Pharmaceutical Companies of Johnson & Johnson announced that FDA approved its ERLEADA (apalutamide), a next-generation androgen receptor inhibitor. The inhibitor is used for the treatment of patients with non-metastatic castration-resistant prostate cancer (NM-CRPC).

Dec-2016: Sanofi Genzyme, business unit of Sanofi announced agreement with Scottish Medicines Consortium (SMC). Following this agreement, Jevtana (cabazitaxel), a product of Sanofi is being used in NHS Scotland for the treatment of metastatic hormone-refractory prostate cancer (mHRPC) by Scottish Medicines Consortium (SMC).

Scope of the Study

Market Segments covered in the Report:

By Therapy

  • Hormonal Therapy
  • Immunotherapy
  • Chemotherapy
  • Radiotherapy

By Geography

  • North America

US

Canada

Mexico

Rest of North America

  • Europe

Germany

UK

France

Russia

Spain

Italy

Rest of Europe

  • Asia Pacific

China

Japan

India

South Korea

Singapore

Malaysia

Rest of Asia Pacific

  • LAMEA

Brazil

Argentina

UAE

Saudi Arabia

South Africa

Nigeria

Rest of LAMEA

Companies Profiled

  • Sanofi S.A.
  • Johnson and Johnson
  • Pfizer, Inc.
  • Bayer AG
  • Abbott Laboratories
  • GlaxoSmithKline PLC (GSK)
  • Northwest Biotherapeutics, Inc.
  • Active Biotech AB
  • Astellas Pharma, Inc.
  • Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Castrate-resistant Prostate Cancer Market, by Therapy
    • 1.4.2 Global Castrate-resistant Prostate Cancer Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
    • 2.1.2 Market composition
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Recent Developments in Global Castrate-resistant Prostate Cancer Market

Chapter 4. Global Castrate-resistant Prostate Cancer Market by Therapy

  • 4.1 Global Hormonal Therapy Market by Region
  • 4.2 Global Immunotherapy Market by Region
  • 4.3 Global Chemotherapy Market by Region
  • 4.4 Global Radiotherapy Market by Region

Chapter 5. Global Castrate-resistant Prostate Cancer Market by Region

  • 5.1 North America Castrate-resistant Prostate Cancer Market
    • 5.1.1 North America Castrate-resistant Prostate Cancer Market by Therapy
      • 5.1.1.1 North America Hormonal Therapy Market by Country
      • 5.1.1.2 North America Immunotherapy Market by Country
      • 5.1.1.3 North America Chemotherapy Market by Country
      • 5.1.1.4 North America Radiotherapy Market by Country
    • 5.1.2 North America Castrate-resistant Prostate Cancer Market by Country
      • 5.1.2.1 US Castrate-resistant Prostate Cancer Market
        • 5.1.2.1.1 US Castrate-resistant Prostate Cancer Market by Therapy
      • 5.1.2.2 Canada Castrate-resistant Prostate Cancer Market
        • 5.1.2.2.1 Canada Castrate-resistant Prostate Cancer Market by Therapy
      • 5.1.2.3 Mexico Castrate-resistant Prostate Cancer Market
        • 5.1.2.3.1 Mexico Castrate-resistant Prostate Cancer Market by Therapy
      • 5.1.2.4 Rest of North America Castrate-resistant Prostate Cancer Market
        • 5.1.2.4.1 Rest of North America Castrate-resistant Prostate Cancer Market by Therapy
  • 5.2 Europe Castrate-resistant Prostate Cancer Market
    • 5.2.1 Europe Castrate-resistant Prostate Cancer Market by Therapy
      • 5.2.1.1 Europe Hormonal Therapy Market by Country
      • 5.2.1.2 Europe Immunotherapy Market by Country
      • 5.2.1.3 Europe Chemotherapy Market by Country
      • 5.2.1.4 Europe Radiotherapy Market by Country
    • 5.2.2 Europe Castrate-resistant Prostate Cancer Market by Country
      • 5.2.2.1 Germany Castrate-resistant Prostate Cancer Market
        • 5.2.2.1.1 Germany Castrate-resistant Prostate Cancer Market by Therapy
      • 5.2.2.2 UK Castrate-resistant Prostate Cancer Market
        • 5.2.2.2.1 UK Castrate-resistant Prostate Cancer Market by Therapy
      • 5.2.2.3 France Castrate-resistant Prostate Cancer Market
        • 5.2.2.3.1 France Castrate-resistant Prostate Cancer Market by Therapy
      • 5.2.2.4 Russia Castrate-resistant Prostate Cancer Market
        • 5.2.2.4.1 Russia Castrate-resistant Prostate Cancer Market by Therapy
      • 5.2.2.5 Spain Castrate-resistant Prostate Cancer Market
        • 5.2.2.5.1 Spain Castrate-resistant Prostate Cancer Market by Therapy
      • 5.2.2.6 Italy Castrate-resistant Prostate Cancer Market
        • 5.2.2.6.1 Italy Castrate-resistant Prostate Cancer Market by Therapy
      • 5.2.2.7 Rest of Europe Castrate-resistant Prostate Cancer Market
        • 5.2.2.7.1 Rest of Europe Castrate-resistant Prostate Cancer Market by Therapy
  • 5.3 Asia Pacific Castrate-resistant Prostate Cancer Market
    • 5.3.1 Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy
      • 5.3.1.1 Asia Pacific Hormonal Therapy Market by Country
      • 5.3.1.2 Asia Pacific Immunotherapy Market by Country
      • 5.3.1.3 Asia Pacific Chemotherapy Market by Country
      • 5.3.1.4 Asia Pacific Radiotherapy Market by Country
    • 5.3.2 Asia Pacific Castrate-resistant Prostate Cancer Market by Country
      • 5.3.2.1 China Castrate-resistant Prostate Cancer Market
        • 5.3.2.1.1 China Castrate-resistant Prostate Cancer Market by Therapy
      • 5.3.2.2 Japan Castrate-resistant Prostate Cancer Market
        • 5.3.2.2.1 Japan Castrate-resistant Prostate Cancer Market by Therapy
      • 5.3.2.3 India Castrate-resistant Prostate Cancer Market
        • 5.3.2.3.1 India Castrate-resistant Prostate Cancer Market by Therapy
      • 5.3.2.4 South Korea Castrate-resistant Prostate Cancer Market
        • 5.3.2.4.1 South Korea Castrate-resistant Prostate Cancer Market by Therapy
      • 5.3.2.5 Singapore Castrate-resistant Prostate Cancer Market
        • 5.3.2.5.1 Singapore Castrate-resistant Prostate Cancer Market by Therapy
      • 5.3.2.6 Malaysia Castrate-resistant Prostate Cancer Market
        • 5.3.2.6.1 Malaysia Castrate-resistant Prostate Cancer Market by Therapy
      • 5.3.2.7 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market
        • 5.3.2.7.1 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy
  • 5.4 LAMEA Castrate-resistant Prostate Cancer Market
    • 5.4.1 LAMEA Castrate-resistant Prostate Cancer Market by Therapy
      • 5.4.1.1 LAMEA Hormonal Therapy Market by Country
      • 5.4.1.2 LAMEA Immunotherapy Market by Country
      • 5.4.1.3 LAMEA Chemotherapy Market by Country
      • 5.4.1.4 LAMEA Radiotherapy Market by Country
    • 5.4.2 LAMEA Castrate-resistant Prostate Cancer Market by Country
      • 5.4.2.1 Brazil Castrate-resistant Prostate Cancer Market
        • 5.4.2.1.1 Brazil Castrate-resistant Prostate Cancer Market by Therapy
      • 5.4.2.2 Argentina Castrate-resistant Prostate Cancer Market
        • 5.4.2.2.1 Argentina Castrate-resistant Prostate Cancer Market by Therapy
      • 5.4.2.3 UAE Castrate-resistant Prostate Cancer Market
        • 5.4.2.3.1 UAE Castrate-resistant Prostate Cancer Market by Therapy
      • 5.4.2.4 Saudi Arabia Castrate-resistant Prostate Cancer Market
        • 5.4.2.4.1 Saudi Arabia Castrate-resistant Prostate Cancer Market by Therapy
      • 5.4.2.5 South Africa Castrate-resistant Prostate Cancer Market
        • 5.4.2.5.1 South Africa Castrate-resistant Prostate Cancer Market by Therapy
      • 5.4.2.6 Nigeria Castrate-resistant Prostate Cancer Market
        • 5.4.2.6.1 Nigeria Castrate-resistant Prostate Cancer Market by Therapy
      • 5.4.2.7 Rest of LAMEA Castrate-resistant Prostate Cancer Market
        • 5.4.2.7.1 Rest of LAMEA Castrate-resistant Prostate Cancer Market by Therapy

Chapter 6. Company Profiles

  • 6.1 Sanofi S.A.
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Segmental and Regional Analysis
    • 6.1.4 Research & Development Expense
    • 6.1.5 Recent strategies and developments:
      • 6.1.5.1 Partnerships, Collaborations, and Agreements:
  • 6.2 Johnson and Johnson
    • 6.2.1 Company Overview
    • 6.2.2 Financial Analysis
    • 6.2.3 Segmental &Regional Analysis
    • 6.2.4 Research & Development Expenses
    • 6.2.1 Recent strategies and developments:
      • 6.2.1.1 Approvals:
  • 6.3 Pfizer, Inc.
    • 6.3.1 Company Overview
    • 6.3.2 Financial Analysis
    • 6.3.3 Segmental and Regional Analysis
    • 6.3.4 Recent strategies and developments:
      • 6.3.4.1 Approvals:
  • 6.4 Bayer AG
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Segmental and Regional Analysis
    • 6.4.4 Research & Development Expense
    • 6.4.5 Recent strategies and developments:
      • 6.4.5.1 Approvals:
  • 6.5 Abbott Laboratories
    • 6.5.1 Company Overview
    • 6.5.2 Financial Analysis
    • 6.5.3 Segmental and Regional Analysis
    • 6.5.4 Research & Development Expense
  • 6.6 GlaxoSmithKline PLC (GSK)
    • 6.6.1 Company Overview
    • 6.6.2 Financial Analysis
    • 6.6.3 Segmental and Regional Analysis
    • 6.6.4 Research & Development Expense
  • 6.7 Northwest Biotherapeutics, Inc.
    • 6.7.1 Company Overview
    • 6.7.2 Financial Analysis
    • 6.7.3 Research & Development Expense
  • 6.8 Active Biotech AB
    • 6.8.1 Company Overview
    • 6.8.2 Financial Analysis
    • 6.8.3 Research & Development Expense
  • 6.9 Astellas Pharma, Inc.
    • 6.9.1 Company Overview
    • 6.9.2 Financial Analysis
    • 6.9.3 Regional Analysis
    • 6.9.4 Research & Development Expense
    • 6.9.5 Recent strategies and developments:
      • 6.9.5.1 Product Launches and Product Expansions:
  • 6.10. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
    • 6.10.1 Company Overview
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.